Table I.
miRNAs which reverse multi-drug resistance in gastric cancer.
| MicroRNA | Dysregulation | Effect on drug resistance | Corresponding drugs | Pathway/target | Refs. |
|---|---|---|---|---|---|
| miR-185 | ↓ | Reversing | ADR, 5-FU, OXA; DOX, DDP | MDR1/P-gp, MRP, Bcl-2; ARC/RUNX3 | (44,45) |
| miR-218 | ↓ | Reversing | ADR, OXA, 5-FU | SMO/P-gp/Bax/Bcl2 | (33,46) |
| miR-145 | ↓ | Reversing | 5-FU, DDP | CD44 | (47) |
| miR-101 | ↓ | Reversing | DDP, VCR | ANXA2; VEGF-C | (48,49) |
| miR-495 | ↓ | Reversing | PTX, DOX | MDR1/ABCB1 | (50) |
| miR-126 | ↓ | Reversing | ADR, VCR | EZH2 | (51) |
| miR-508-5p | ↓ | Reversing | / | ABCB1/ZNRD1 | (52) |
| miR-27b | ↓ | Reversing | ADR, VCR, 5-FU, DDP | CCNG1/P53/miR-508-5p | (53) |
| miR-30a | ↓ | Reversing | DDP, 5-FU | EMT | (30,54,55) |
| miR-107 | ↓ | Reversing | OXA, PTX, ADR, 5-FU | Lin28 | (56) |
| miR-BART20-5p | ↓ | Reversing | 5-FU, docetaxel | BAD | (57) |
| miR-23b-3p | ↓ | Reversing | 5-FU, VCR, DDP | ATG12/HMGB2/autophagy | (34) |
| miR-129-5p | ↓ | Reversing | VCR, ADR | ABCB1/ABCC5/ABCG1 | (58) |
ADR, adriamycin; 5-FU, 5-fluorouracil; OXA, oxaliplatin; DOX, doxorubicin; DDP, cisplatin; VCR, vincristine; PTX, paclitaxel; MDR1, multi- drug resistance protein 1; P-gp/ABCB1, P-glycoprotein 1; MRP, multi-drug resistance-associated protein; Bcl-2, B-cell lymphoma-2; ARC, apoptosis repressor with caspase recruitment domain; RUNX3, runt-related transcription factor 3; SMO, smoothened; Bax, Bcl-2-associated X protein; ANXA2, Annexin A2; VEGF-C, vascular endothelial growth factor C; EZH2, Enhancer of Zeste Homolog 2; ZNRD1, Zinc ribbon domain-containing 1; EMT, epithelial-mesenchymal transition; BAD, Bcl-2-associated death promoter; ATG12, autophagy-related gene 12; HMGB2, high mobility group box 2;ABCC5, multi-drug resistance-associated protein 5; ABCG1, ATP-binding cassette sub-family G member 1; /, not mentioned; ↓, downregulation.